Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:HIK
- CUSIP: N/A
- Web: N/A
- Market Cap: £4.03 billion
- Outstanding Shares: 240,959,000
- 50 Day Moving Avg: GBX 1,866.09
- 200 Day Moving Avg: GBX 1,888.75
- 52 Week Range: GBX 1,573 - GBX 2,703
Sales & Book Value:
- Trailing P/E Ratio: 25.17
- P/E Growth: 0.93
- Annual Revenue: £1.95 billion
- Price / Sales: 2.06
- Book Value: GBX 9.94 per share
- Price / Book: 1.68
- Average Volume: 845,563 shs.
Frequently Asked Questions for Hikma Pharmaceuticals Plc (LON:HIK)
What is Hikma Pharmaceuticals Plc's stock symbol?
Hikma Pharmaceuticals Plc trades on the London Stock Exchange (LON) under the ticker symbol "HIK."
How often does Hikma Pharmaceuticals Plc pay dividends? What is the dividend yield for Hikma Pharmaceuticals Plc?
Hikma Pharmaceuticals Plc announced a dividend on Wednesday, March 15th. Stockholders of record on Thursday, April 6th will be paid a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date is Thursday, April 6th. This is a positive change from Hikma Pharmaceuticals Plc's previous dividend of $0.21. The official announcement can be accessed at this link. View Hikma Pharmaceuticals Plc's Dividend History.
Where is Hikma Pharmaceuticals Plc's stock going? Where will Hikma Pharmaceuticals Plc's stock price be in 2017?
10 brokerages have issued 1-year price objectives for Hikma Pharmaceuticals Plc's stock. Their predictions range from GBX 1,450 to GBX 2,900. On average, they expect Hikma Pharmaceuticals Plc's stock price to reach GBX 2,177.10 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals Plc.
Who are some of Hikma Pharmaceuticals Plc's key competitors?
Some companies that are related to Hikma Pharmaceuticals Plc include Antofagasta plc (ANTO), ITV plc (ITV), Ashtead Group plc (AHT), Whitbread plc (WTB), The Sage Group plc (SGE), Burberry Group plc (BRBY), Standard Life Plc (SL), Persimmon plc (PSN), Kingfisher plc (KGF), United Utilities Group PLC (UU), Paddy Power Betfair Plc (PPB), Tui AG (TUI), Intertek Group plc (ITRK), Randgold Resources Limited (RRS), Dcc Plc (DCC), Hargreaves Lansdown PLC (HL), British Land Company PLC (BLND) and Taylor Wimpey plc (TW).
How do I buy Hikma Pharmaceuticals Plc stock?
Shares of Hikma Pharmaceuticals Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Hikma Pharmaceuticals Plc stock cost?
One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately GBX 1,671.
Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||2 Sell Ratings, 3 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.30)|
|Consensus Price Target: ||GBX 2,177.10|
Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
(Data available from 5/25/2015 forward)
|5/22/2017||JPMorgan Chase & Co.||Reiterated Rating||Neutral||GBX 1,800 -> GBX 1,500|
|5/19/2017||Numis Securities Ltd||Reiterated Rating||Add||GBX 2,000|
|5/17/2017||Jefferies Group LLC||Downgrade||Underperform||GBX 2,162 -> GBX 1,450|
|5/5/2017||HSBC Holdings plc||Reiterated Rating||Reduce||GBX 1,800|
|4/4/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 2,550|
|3/30/2017||Peel Hunt||Reiterated Rating||Buy|
|11/30/2016||AlphaValue||Reiterated Rating||Buy||GBX 2,431|
|11/16/2016||Citigroup Inc||Reiterated Rating||Neutral|
|11/15/2016||Morgan Stanley||Upgrade||Equal Weight -> Overweight||GBX 2,500 -> GBX 2,200|
|9/9/2016||Barclays PLC||Reiterated Rating||Overweight||GBX 2,900|
|3/16/2016||Panmure Gordon||Upgrade||Buy||GBX 2,120|
|9/15/2015||Goldman Sachs Group Inc||Reiterated Rating||Buy|
Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)
Current Year EPS Consensus Estimate: $1.19 EPS
Dividend History by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Hikma Pharmaceuticals Plc (LON:HIK)Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/19/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 1,790||£895,000|
|12/16/2016||Mazen Darwazah||Insider||Buy||90,730||GBX 1,849||£1,677,597.70|
|12/12/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 1,707||£853,500|
|12/9/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 1,723||£861,500|
|12/6/2016||Ali Al-Husry||Insider||Buy||100,000||GBX 1,682||£1,682,000|
|12/5/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 1,674||£837,000|
|12/2/2016||Mazen Darwazah||Insider||Buy||50,000||GBX 1,662||£831,000|
|12/1/2016||Mazen Darwazah||Insider||Buy||50,000||GBX 1,674||£837,000|
|11/30/2016||Said Darwazah||Insider||Buy||50,000||GBX 1,662||£831,000|
|9/28/2016||Said Darwazah||Insider||Buy||10,000||GBX 2,085||£208,500|
|9/27/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 2,094||£1,047,000|
|9/26/2016||Said Darwazah||Insider||Buy||50,000||GBX 2,078||£1,039,000|
|9/23/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 2,099||£1,049,500|
|9/21/2016||Ali Al-Husry||Insider||Buy||50,000||GBX 2,138||£1,069,000|
|4/11/2016||J. Castellani,John||Insider||Buy||2,500||GBX 2,103||£52,575|
|3/21/2016||Pickering ,Robert||Insider||Buy||2,500||GBX 1,856||£46,400|
Headline Trends for Hikma Pharmaceuticals Plc (LON:HIK)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
Hikma Pharmaceuticals Plc (HIK) Chart for Thursday, May, 25, 2017